MX2017004983A - Metodos para usar interleucina 10 para tratar enfermedades y trastornos. - Google Patents
Metodos para usar interleucina 10 para tratar enfermedades y trastornos.Info
- Publication number
- MX2017004983A MX2017004983A MX2017004983A MX2017004983A MX2017004983A MX 2017004983 A MX2017004983 A MX 2017004983A MX 2017004983 A MX2017004983 A MX 2017004983A MX 2017004983 A MX2017004983 A MX 2017004983A MX 2017004983 A MX2017004983 A MX 2017004983A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- interleukin
- disorders
- treating diseases
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067337P | 2014-10-22 | 2014-10-22 | |
| PCT/US2015/056383 WO2016064817A1 (en) | 2014-10-22 | 2015-10-20 | Methods of using interleukin-10 for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017004983A true MX2017004983A (es) | 2017-11-13 |
Family
ID=55761394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004983A MX2017004983A (es) | 2014-10-22 | 2015-10-20 | Metodos para usar interleucina 10 para tratar enfermedades y trastornos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10143726B2 (enExample) |
| EP (1) | EP3209320B1 (enExample) |
| JP (1) | JP6675394B2 (enExample) |
| KR (1) | KR20170084033A (enExample) |
| CN (1) | CN107106655A (enExample) |
| AU (1) | AU2015336101A1 (enExample) |
| CA (1) | CA2963995A1 (enExample) |
| ES (1) | ES2941234T3 (enExample) |
| MX (1) | MX2017004983A (enExample) |
| WO (1) | WO2016064817A1 (enExample) |
| ZA (1) | ZA201702214B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| RU2593715C2 (ru) | 2010-09-15 | 2016-08-10 | Рэндэлл Дж. МРСНИ | Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина |
| CN117298254A (zh) | 2014-05-07 | 2023-12-29 | 应用分子转运公司 | 用于口服递送生物活性货物的cholix毒素衍生的融合分子 |
| WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| KR20180020141A (ko) | 2015-05-28 | 2018-02-27 | 아르모 바이오사이언시스 인코포레이티드 | 암 치료에 사용되는 peg화된 인터류킨-10 |
| CN108025040A (zh) | 2015-08-25 | 2018-05-11 | 阿尔莫生物科技股份有限公司 | 使用白介素-10治疗疾病和病症的方法 |
| WO2017123557A1 (en) | 2016-01-11 | 2017-07-20 | Armo Biosciences, Inc. | Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same |
| ES2911075T3 (es) | 2018-11-07 | 2022-05-17 | Applied Molecular Transport Inc | Constructos de administración para transcitosis y métodos relacionados |
| MX2021005382A (es) | 2018-11-07 | 2021-11-12 | Applied Molecular Transport Inc | Vehiculos derivados de cholix para suministro oral de carga util heterologa. |
| JP2022519586A (ja) * | 2019-02-04 | 2022-03-24 | ゼネティック バイオサイエンシーズ インコーポレイテッド | 糖ポリシアル酸化治療用タンパク質を使用する方法 |
| JP2022521428A (ja) | 2019-02-25 | 2022-04-07 | ザ・ユニバーシティ・オブ・シカゴ | 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物 |
| KR20220066056A (ko) | 2019-08-16 | 2022-05-23 | 어플라이드 몰레큘라 트랜스포트 인크. | 조성물, 제형, 및 인터루킨 제조 및 정제 |
| WO2021102063A1 (en) | 2019-11-20 | 2021-05-27 | Anwita Biosciences, Inc. | Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications |
| IL298007A (en) | 2020-05-12 | 2023-01-01 | Regeneron Pharma | Novel il10 agonists and methods of use thereof |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1202840A (en) | 1985-06-10 | 1986-04-08 | Jonathan R. Kleinsasser | Combination wet and dry feeder for animals |
| JPS63152393A (ja) | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | グリコシル誘導体 |
| US5714585A (en) | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US5032396A (en) | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
| US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
| US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
| US5229115A (en) | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5156301A (en) | 1990-12-17 | 1992-10-20 | Imi Cornelius Inc. | Constant ratio post-mix beverage dispensing valve |
| KR100207766B1 (ko) | 1991-01-16 | 1999-07-15 | 둘락 노먼 씨. | 신생물 질환 치료용 인터루킨-10 조성물 |
| ZA92304B (en) | 1991-01-16 | 1992-09-30 | Schering Corp | Use of interleukin-10 in adoptive immunotherapy of cancer |
| US5624823A (en) | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| EP0681589A1 (en) | 1993-02-01 | 1995-11-15 | Université Libre de Bruxelles | Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10 |
| US5328989A (en) | 1993-03-05 | 1994-07-12 | Schering-Plough | Purification of human interleukin-10 from a cell culture medium |
| US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| WO1994022473A1 (en) | 1993-04-01 | 1994-10-13 | University Of Washington | Use of interleukin 7 to improve vaccine potency |
| US5665345A (en) | 1993-05-24 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting viral replication using IL-10 |
| HUT73463A (en) | 1993-07-26 | 1996-08-28 | Schering Corp | Agonists and antagonists of human interleukin-10 |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| FI962813A0 (fi) | 1994-01-20 | 1996-07-11 | Schering Corp | IL-10:n käyttö perifeerisen veren yksitumaisten solujen sytolyyttisen aktiivisuuden stimuloimiseen |
| US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6410008B1 (en) | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5866134A (en) | 1995-03-24 | 1999-02-02 | Schering Corporation | Method for enhancing the antibody response to specific antigens with Interleukin-10 |
| US5770190A (en) | 1995-07-14 | 1998-06-23 | Schering Corporation | Method of treatment of acute leukemia with inteleukin-10 |
| GB2304047A (en) | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
| US5744451A (en) | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5759859A (en) | 1996-07-15 | 1998-06-02 | United States Of America As Represented By The Secretary Of The Army | Sensor and method for detecting trace underground energetic materials |
| US5945097A (en) | 1996-09-06 | 1999-08-31 | Schering Corporation | Method for lowering cholesterol levels with interleukin-10 |
| US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| US6660258B1 (en) | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| AU755051B2 (en) | 1998-01-07 | 2002-12-05 | Debio Recherche Pharmaceutique S.A. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| US6428985B1 (en) | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| JP2002532556A (ja) | 1998-12-22 | 2002-10-02 | シェリング・コーポレーション | Ｃ型肝炎ウイルス感染のインターロイキン−１０での処置 |
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| AU5827000A (en) | 1999-07-16 | 2001-02-05 | Maria Teresa Bejarano | Viral il-10 uses |
| US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
| AU2001231532A1 (en) | 2000-02-11 | 2001-08-20 | Maxygen Aps | Improved interleukin 10 |
| US20030186386A1 (en) | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
| EP2295450B1 (en) | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
| JP2002142770A (ja) | 2000-11-08 | 2002-05-21 | Dnavec Research Inc | 循環系への遺伝子送達用パラミクソウイルスベクター |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| EP1234583A1 (en) | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
| WO2002085300A2 (en) | 2001-04-23 | 2002-10-31 | The Regents Of The University Of California | Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts |
| GB0212648D0 (en) | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
| EP1391513A1 (en) | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| ES2343518T3 (es) | 2002-09-09 | 2010-08-03 | Hanall Biopharma Co., Ltd. | Polipeptidos interferon alfa modificados resistentes a proteasas. |
| US20040142893A1 (en) * | 2002-10-21 | 2004-07-22 | Uichi Ikeda | Methods for treating and preventing vascular disease |
| AU2003280315A1 (en) | 2002-11-14 | 2004-06-03 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| ES2312820T3 (es) | 2002-11-29 | 2009-03-01 | Maria Grazia Roncarolo | Paramicina e il-10 para el tratamiento de enfermedades autoinmunes. |
| WO2004056850A2 (en) | 2002-12-19 | 2004-07-08 | Vib Vzw | Mutant proteins showing increased secretion |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| KR101162908B1 (ko) | 2002-12-26 | 2012-07-06 | 마운틴 뷰 파마슈티컬즈, 인크. | 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체 |
| AU2004217894B2 (en) | 2003-03-03 | 2010-07-15 | Bracco International B.V. | Peptides that specifically bind HGF receptor (cMet) and uses thereof |
| EP1613274B1 (en) | 2003-04-15 | 2010-03-03 | GlaxoSmithKline LLC | Human il-18 substitution mutants and their conjugates |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| WO2005033307A1 (ja) | 2003-09-30 | 2005-04-14 | Kyowa Hakko Kogyo Co., Ltd. | 新規のリフォールディング方法およびその方法によって得られたタンパク質 |
| WO2005052159A1 (en) | 2003-11-28 | 2005-06-09 | The University Of Sydney | Latent phase viral interleukin-10-(vii-10) and uses thereof |
| PL1699822T3 (pl) | 2003-12-30 | 2008-08-29 | Merck Patent Gmbh | Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie |
| US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
| EP1725589A1 (en) | 2004-03-11 | 2006-11-29 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
| US20060046961A1 (en) | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| CN100334112C (zh) | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
| CA2591297C (en) | 2004-12-09 | 2015-01-13 | Stephen D. Gillies | Il-7 variants with reduced immunogenicity |
| GB0500643D0 (en) | 2005-01-13 | 2005-02-23 | Renovo Ltd | Medicaments |
| WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| UY29460A1 (es) | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| EP1901769A2 (en) | 2005-05-02 | 2008-03-26 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
| DE602006011311D1 (de) | 2005-05-31 | 2010-02-04 | Univ Colorado | Il-10 mutante |
| EP1910513B1 (en) | 2005-07-01 | 2016-08-10 | John Schrader | Methods of isolating antibody secreting cells from blood samples of immunized animals and generating monoclonal antibodies from said antibody secreting cells. |
| EP1746161A1 (en) | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
| DK1931704T3 (da) | 2005-10-04 | 2011-03-14 | Zymogenetics L L C | Frembringelse og rensning af IL-29 |
| WO2007061657A2 (en) | 2005-11-14 | 2007-05-31 | The Brigham & Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| US7868139B2 (en) | 2006-01-24 | 2011-01-11 | Uab Research Foundation | Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases |
| US20080081031A1 (en) | 2006-09-28 | 2008-04-03 | Schering Corporation | Use of Pegylated IL-10 to Treat Cancer |
| WO2008041953A2 (en) | 2006-10-05 | 2008-04-10 | Agency For Science, Technology And Research | Dengue diagnosis and treatment |
| JP5220025B2 (ja) | 2006-12-04 | 2013-06-26 | プロメディオール， インコーポレイテッド | 線維症疾患を処置するための併用療法 |
| KR101775929B1 (ko) | 2007-01-19 | 2017-09-07 | 카이 파마슈티컬즈 | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 |
| DE08786222T1 (de) | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| WO2009036568A1 (en) | 2007-09-19 | 2009-03-26 | University Health Network | Methods and compositions for treating tumors and viral infections |
| WO2009052454A2 (en) | 2007-10-19 | 2009-04-23 | University Of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
| MX2010012579A (es) * | 2008-05-29 | 2010-12-20 | Squibb Bristol Myers Co | Metodos para predecir respuesta de pacientes a modulacion de la via co-estimuladora. |
| WO2010022227A1 (en) * | 2008-08-20 | 2010-02-25 | Schering Corporation | Methods for monitoring il-10 therapy |
| EP2379115B1 (en) | 2008-12-17 | 2017-10-25 | Merck Sharp & Dohme Corp. | Mono- and di-peg il-10 production; and uses |
| AU2010308030B2 (en) | 2009-10-12 | 2014-05-29 | Pfizer Inc. | Cancer treatment |
| GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
| WO2011159878A1 (en) | 2010-06-16 | 2011-12-22 | Abbott Laboratories | Comparison of protein samples |
| TR201809437T4 (tr) | 2010-07-09 | 2018-07-23 | Affibody Ab | Polipeptitler. |
| US8759617B2 (en) | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
| WO2012050923A2 (en) | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action |
| CN103547590B (zh) | 2010-09-28 | 2017-11-28 | 埃格里昂制药股份有限公司 | 高度可溶性瘦蛋白 |
| SI3757126T1 (sl) * | 2010-11-05 | 2025-12-31 | Novartis Ag | Postopki za zdravljenje psoriatičnega artritisa z antagonisti il-17 |
| BR112013024395B1 (pt) | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
| CN102145178B (zh) | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| JP2015506373A (ja) | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子１５（ｇｄｆ−１５）ポリペプチド |
| HK1205746A1 (en) | 2012-02-29 | 2015-12-24 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates and their uses |
| US20150118244A1 (en) | 2012-05-10 | 2015-04-30 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
| CN106913865A (zh) | 2013-04-18 | 2017-07-04 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
| JP2016526014A (ja) | 2013-04-24 | 2016-09-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−１０組成物及びその使用 |
| EP3010527B1 (en) | 2013-06-17 | 2018-08-08 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| HK1226308A1 (zh) | 2013-08-30 | 2017-09-29 | Armo Biosciences, Inc. | 使用白细胞介素-10治疗疾病和病症的方法 |
| US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US20160375101A1 (en) | 2014-01-15 | 2016-12-29 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| MA39711A (fr) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| CN106573072A (zh) * | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
| EP3237441A4 (en) | 2014-12-23 | 2018-06-06 | Armo Biosciences, Inc. | Methods of improving yield in recombinant protein production |
| EP3285799A4 (en) | 2015-03-11 | 2018-08-08 | Nektar Therapeutics | Conjugates of an il-7 moiety and an polymer |
| KR20180020141A (ko) | 2015-05-28 | 2018-02-27 | 아르모 바이오사이언시스 인코포레이티드 | 암 치료에 사용되는 peg화된 인터류킨-10 |
-
2015
- 2015-10-20 EP EP15852286.2A patent/EP3209320B1/en active Active
- 2015-10-20 JP JP2017521564A patent/JP6675394B2/ja active Active
- 2015-10-20 MX MX2017004983A patent/MX2017004983A/es unknown
- 2015-10-20 ES ES15852286T patent/ES2941234T3/es active Active
- 2015-10-20 CN CN201580069348.9A patent/CN107106655A/zh active Pending
- 2015-10-20 AU AU2015336101A patent/AU2015336101A1/en not_active Abandoned
- 2015-10-20 KR KR1020177011082A patent/KR20170084033A/ko not_active Withdrawn
- 2015-10-20 WO PCT/US2015/056383 patent/WO2016064817A1/en not_active Ceased
- 2015-10-20 US US15/513,825 patent/US10143726B2/en active Active
- 2015-10-20 CA CA2963995A patent/CA2963995A1/en not_active Abandoned
-
2017
- 2017-03-29 ZA ZA2017/02214A patent/ZA201702214B/en unknown
-
2018
- 2018-10-23 US US16/168,345 patent/US10653751B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170246252A1 (en) | 2017-08-31 |
| JP2017533201A (ja) | 2017-11-09 |
| AU2015336101A1 (en) | 2017-04-20 |
| US20190046613A1 (en) | 2019-02-14 |
| EP3209320A4 (en) | 2018-07-18 |
| JP6675394B2 (ja) | 2020-04-01 |
| ZA201702214B (en) | 2019-09-25 |
| KR20170084033A (ko) | 2017-07-19 |
| EP3209320B1 (en) | 2023-03-08 |
| EP3209320A1 (en) | 2017-08-30 |
| US10653751B2 (en) | 2020-05-19 |
| CN107106655A (zh) | 2017-08-29 |
| WO2016064817A1 (en) | 2016-04-28 |
| CA2963995A1 (en) | 2016-04-28 |
| ES2941234T3 (es) | 2023-05-19 |
| US10143726B2 (en) | 2018-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015014438A (es) | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. | |
| MX2017004983A (es) | Metodos para usar interleucina 10 para tratar enfermedades y trastornos. | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| HUE049014T2 (hu) | Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére | |
| MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
| MX380777B (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| HUE051488T2 (hu) | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére | |
| LT3294323T (lt) | Adenoasocijuotas virusas, skirtas terapiniam pristatymui į centrinę nervų sistemą | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| MX384192B (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| MX2016005915A (es) | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. | |
| SG11201609014TA (en) | Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy | |
| EP3148569A4 (en) | Therapeutic tratment of skin disease with recombinant commensal skin microorganisms | |
| HK1226308A1 (zh) | 使用白细胞介素-10治疗疾病和病症的方法 | |
| MY199091A (en) | Therapeutic compounds | |
| EA201591648A1 (ru) | Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4 | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| MX2018007307A (es) | Conjugados de peptidos y oligonucleotidos. | |
| EA201790991A1 (ru) | Способ лечения с использованием пегилированного интерферона | |
| PH12017501979A1 (en) | Pharmaceutical compound | |
| HK1242217A1 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| FR3021219B1 (fr) | Oligo-porphyranes, procede et medicament | |
| MA40574A (fr) | Traitement de maladies fibrotiques |